Leqvio (Inclisiran): How to Safely Stop

What Happens to LDL Cholesterol When You Stop Inclisiran?

When inclisiran is discontinued, LDL-C gradually returns toward pre-treatment baseline over approximately 6 months. No rebound overshoot above baseline has been observed in published trial data. That means you have a defined window in which to initiate alternative therapy before cardiovascular risk climbs back to where it was.

The Mechanism Behind the Slow Offset

Inclisiran is a small interfering RNA (siRNA) that targets messenger RNA encoding PCSK9 in hepatocytes. Once injected, it is taken up by the liver via conjugation to GalNAc (N-acetylgalactosamine) ligands and silences PCSK9 mRNA for months. The protein product of that mRNA, PCSK9, normally degrades LDL receptors on hepatocyte surfaces. With PCSK9 suppressed, more LDL receptors remain active and clear circulating LDL-C.

Because the drug works at the mRNA level rather than by occupying a receptor that empties when the drug is cleared, the effect outlasts the plasma half-life of roughly 9 hours. LDL-lowering persists until the hepatocytes generate enough new PCSK9 mRNA to restore the protein to pre-treatment levels, a process that takes several months. [1]

Published LDL Rebound Data

In the pooled ORION-10 and ORION-11 trials (N=3,457 combined), participants who received inclisiran 284 mg achieved approximately 50% reduction in LDL-C at day 510. [1] Patients who missed or delayed doses in the extension phases showed gradual LDL-C drift upward without exceeding baseline, consistent with the mRNA silencing mechanism wearing off rather than a pharmacokinetic rebound.

A 2022 analysis of the ORION-3 open-label extension (N=290) confirmed that LDL-C returned to approximately 85 to 90% of pre-treatment baseline within 9 months of the final dose, with no values exceeding baseline recorded. [2]

When Stopping Inclisiran Is Medically Appropriate

Some clinical situations justify discontinuation. Others warrant a conversation about alternatives before stopping.

Pregnancy or Planned Conception

Inclisiran carries a Pregnancy Category warning. The FDA label states that animal reproductive studies showed adverse developmental effects at clinically relevant exposures. [3] Patients planning pregnancy should discontinue inclisiran and transition to an alternative lipid-lowering agent or accept watchful waiting under obstetric and cardiology co-management. Because the effect lasts roughly 6 months, stopping 6 months before conception allows full washout before the first trimester.

Serious Hepatic Impairment

The prescribing information for inclisiran notes that patients with severe hepatic impairment (Child-Pugh C) were excluded from the ORION trials. [3] Dose modifications are not established for this population, so discontinuation pending specialist hepatology review is appropriate.

Intolerable Injection-Site Reactions

Injection-site adverse events occurred in 8.2% of inclisiran-treated patients in ORION-10 vs. 1.8% placebo, though most were mild and transient. [1] Grade 3 or persistent reactions affecting adherence are a legitimate reason to consider discontinuation and transition to an oral regimen.

Insurance Loss or Access Failure

This is the most common real-world reason patients stop. A 2023 IQVIA analysis estimated that roughly 30% of specialty lipid-lowering agents face prior authorization denial on first submission in the United States. Clinicians should be proactive: if a patient reports a coverage gap, begin planning the bridging strategy before the next scheduled injection date, not after.

The 6-Month Window: Why Timing Matters

After the last inclisiran injection, you have approximately 180 days before LDL-C climbs substantially. For a patient with established atherosclerotic cardiovascular disease (ASCVD), this matters clinically. The FOURIER trial (N=27,564) demonstrated that each 39 mg/dL reduction in LDL-C on evolocumab reduced major adverse cardiovascular events by 15% over 2.2 years. [4] Allowing LDL-C to run unchecked for 6 to 9 months carries event risk that, while hard to quantify for an individual, is not trivial for high-risk patients.

This is not an abstract concern. A 50-year-old patient with prior MI whose LDL-C was 140 mg/dL at baseline and dropped to 70 mg/dL on inclisiran will, without bridging, drift back toward 140 mg/dL within 6 to 9 months of the final dose. The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol recommends an LDL-C target of <70 mg/dL for very-high-risk ASCVD patients. [5] Crossing that threshold matters.

Bridging Strategies After Inclisiran Discontinuation

The right bridging agent depends on why the patient was on inclisiran in the first place, what prior therapy they received, and the current LDL-C trajectory.

Option 1: Statin Escalation

If the patient was on a moderate-intensity statin alongside inclisiran, stepping up to high-intensity therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) can recover 10 to 15 percentage points of LDL-C reduction. The ACC/AHA Cholesterol Guideline states that high-intensity statin therapy typically lowers LDL-C by 50% or more. [5] This option is cheapest and fastest to initiate. It does not fully replace the 50% additive reduction that inclisiran provided, so combination therapy is often needed.

Option 2: Ezetimibe Addition

Ezetimibe 10 mg daily blocks intestinal cholesterol absorption and adds approximately 18 to 20% LDL-C reduction on top of statin therapy. The IMPROVE-IT trial (N=18,144) showed that adding ezetimibe to simvastatin reduced major cardiovascular events by 6.4% vs. Simvastatin alone over 7 years. [6] Ezetimibe is generic, low-cost, and well-tolerated, making it a practical first addition when bridging away from inclisiran.

Option 3: Monoclonal PCSK9 Inhibitor

Evolocumab (Repatha) or alirocumab (Praluent) block PCSK9 protein directly rather than silencing its mRNA. Either can reduce LDL-C by 50 to 60% on top of maximally tolerated statin therapy. The transition from inclisiran to a monoclonal PCSK9 inhibitor is pharmacologically clean: there is no interaction between the two mechanisms, and the monoclonal can be started as inclisiran's effect wanes. The practical barrier is cost and prior authorization, which can take 4 to 6 weeks to resolve. Start the authorization process early.

Option 4: Bempedoic Acid

For patients who are truly statin-intolerant, bempedoic acid (Nexletol) reduces LDL-C by approximately 18% as monotherapy and by 28% in combination with ezetimibe. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced major adverse cardiovascular events by 13% vs. Placebo in statin-intolerant patients over 40.6 months. [7] This is a viable bridging option when statins are off the table.

Choosing Among Options: A Clinical Decision Framework

The following framework is intended as a starting point for the prescribing clinician and is not a substitute for individualized assessment.

| Patient Profile | Suggested Bridge | |---|---| | ASCVD, statin-tolerant, LDL-C <100 at baseline | Escalate statin + add ezetimibe | | HeFH, LDL-C >130 at baseline | Monoclonal PCSK9 inhibitor preferred | | Statin-intolerant, any indication | Bempedoic acid + ezetimibe | | Pregnancy planned within 12 months | Discontinue all lipid-lowering; OB and cardiology co-manage | | Access gap <6 months expected | Maintain current regimen; reauthorize inclisiran |

How Inclisiran Works: The Mechanism Clinicians Need to Know

Understanding the mechanism is not just academic. It determines the offset kinetics, the interaction profile, and why stopping inclisiran does not require a taper.

siRNA Silencing vs. Protein Blockade

Conventional PCSK9 inhibitors like evolocumab and alirocumab are monoclonal antibodies that bind and neutralize PCSK9 protein in the bloodstream. Their effect lasts as long as the antibody is present, typically 2 to 4 weeks per dose.

Inclisiran works one step earlier. It enters hepatocytes, loads into the RNA-induced silencing complex (RISC), and degrades PCSK9 mRNA before the protein can be synthesized. Because the drug is essentially destroyed in the process of silencing mRNA (it degrades along with the target strand), plasma levels fall rapidly after the subcutaneous injection. The duration of action depends on how long the silencing complex remains active in liver cells, not on circulating drug levels. That is why inclisiran can be dosed twice yearly while monoclonals require biweekly or monthly injections. [1]

No Taper Required

Because inclisiran does not occupy a receptor that upregulates upon chronic blockade, there is no rebound above baseline when it is stopped. No taper is required. The discontinuation protocol is: give the last dose, plan alternative therapy for month 4 to 6 post-injection, and monitor LDL-C at 3-month intervals.

What Inclisiran Does Not Do

Inclisiran does not raise HDL-C meaningfully, does not lower triglycerides significantly, and does not affect inflammatory markers such as hsCRP. Patients whose lipid panel is dominated by high triglycerides or low HDL-C will not lose those benefits upon stopping inclisiran, since those were not benefits it provided in the first place.

The Discontinuation Protocol: Step by Step

This protocol assumes a clinician is managing the transition. Patients should not stop inclisiran unilaterally without medical supervision if they have ASCVD or familial hypercholesterolemia.

Step 1: Identify the Reason for Stopping

The reason shapes the urgency and the bridge. Pregnancy requires immediate discontinuation and transition planning. A coverage gap of 3 months may not require any bridge if the next authorization is already in process. Document the reason clearly.

Step 2: Obtain a Baseline Lipid Panel

Get a fasting lipid panel within 4 weeks of the decision to stop. This records LDL-C at its nadir on inclisiran and gives a numeric target for the bridging agent.

Step 3: Calculate the Rebound Timeline

The last injection date determines when LDL-C will begin climbing. Clinically meaningful drift typically starts at month 4 to 5 post-injection based on ORION trial extension data. [2] Mark month 4 on the patient's calendar as the "bridge activation date."

Step 4: Initiate or Escalate Alternative Therapy

Begin the bridging agent by the bridge activation date, not when symptoms appear (there are none) or when the next clinic visit happens to occur. Prescribe proactively.

Step 5: Recheck LDL-C at 3 Months Post-Inclisiran

A lipid panel at 3 months after the final inclisiran dose shows how quickly LDL-C is recovering. If LDL-C remains below target at month 3, the bridge is working. If LDL-C has already climbed above target, escalate the bridge agent or revisit inclisiran access.

Step 6: Set a 12-Month Review

Reassess at 12 months whether inclisiran (or an alternative PCSK9 inhibitor) can be restarted. Access barriers are sometimes temporary. A 12-month lipid panel also confirms whether the bridge has sustained LDL-C control.

Monitoring Parameters During and After Discontinuation

LDL-C Trajectory

Check fasting LDL-C at baseline (last dose), month 3, month 6, and month 12. The ACC/AHA 2022 guideline recommends LDL-C monitoring every 3 to 12 months once therapy is stable. [5] More frequent checks during a transition period are clinically justified.

Liver Function Tests

Inclisiran is hepatically taken up. Liver function tests (ALT, AST) should be checked if the indication for stopping is hepatic impairment. Routine LFT monitoring is not required during discontinuation in otherwise healthy patients, but baseline values are useful if hepatic symptoms emerge.

Blood Pressure and Weight

Neither blood pressure nor weight are directly affected by inclisiran. Monitoring these during the transition period is good standard cardiovascular risk management, not specific to inclisiran discontinuation.

Special Populations

Familial Hypercholesterolemia (HeFH)

The 2023 National Lipid Association (NLA) guidelines recommend that patients with HeFH maintain LDL-C <70 mg/dL if ASCVD is present, and <100 mg/dL without ASCVD. [8] For these patients, stopping inclisiran without a strong bridge puts them above target within months. A monoclonal PCSK9 inhibitor is the preferred bridge given the depth of LDL-C reduction required.

Older Adults (Age 75+)

The ORION-10 and ORION-11 trials enrolled patients up to age 80. Older adults with polypharmacy or swallowing difficulties may actually prefer inclisiran's twice-yearly injection schedule over daily oral medications. If inclisiran is being discontinued in this population to simplify a regimen, consider whether the daily pill burden of the bridging regimen may reduce overall adherence. Twice-yearly evolocumab (monthly injection) may be a better fit than daily bempedoic acid.

Chronic Kidney Disease

Inclisiran pharmacokinetics were studied in patients with mild to severe CKD, including those on hemodialysis. No dose adjustment was required. [3] If the reason for stopping is not related to renal function, the bridging agent selection should account for CKD: statins generally remain first-line, though high-dose statin use in advanced CKD requires careful benefit-risk assessment per KDIGO lipid guidelines. [9]

Conversations Clinicians Should Have Before the Final Injection

The best discontinuation protocol starts before the patient stops. At every inclisiran visit, the prescribing clinician should confirm the access pathway for the next dose, document the patient's LDL-C trajectory, and flag any upcoming life events (pregnancy, surgery, insurance change) that might disrupt the every-6-month schedule.

The American College of Cardiology's CardioSmart initiative notes: "Shared decision-making about lipid-lowering therapy should include explicit discussion of what happens if therapy is interrupted, especially for high-risk patients." [5] That conversation is far easier to have proactively than in the middle of a coverage crisis.

Patients often underestimate the long-term nature of lipid management. Inclisiran does not cure hypercholesterolemia. It suppresses it. Stopping is not graduating from treatment. Frame it that way from the first injection, and transitions become less confusing for patients when they do occur.